DA-1241 a novel GPR119 agonist: Safety, tolerability, pharmacokinetics, and pharmacodynamics: Part 2 of multiple ascending dose study in type 2 diabetes patients

Publication Authors:

Bridgette Franey, Michael Grimm, and Marcus Hompesch

Presented at the European Association for the Study of Diabetes (EASD) meeting, October 2021.

About

DA-1241 is a novel small molecule selective GPR119 agonist. In preclinical studies DA-1241 enhanced metabolic hormones, and improved metabolic control characteristics. The primary objective of Part 2 was to assess safety and tolerability of multiple once daily oral doses of DA-1241 versus placebo and Sitagliptin (SG) in Type 2 Diabetes Mellitus (T2DM). Secondary objectives were to establish pharmacokinetic (PK) and pharmacodynamic (PD) characteristics.

VIEW
DA-1241 a novel GPR119 agonist: Safety, tolerability, pharmacokinetics, and pharmacodynamics: Part 2 of multiple ascending dose study in type 2 diabetes patients thumbnail